Media releases

One-year Vabysmo data show improved vision, with more than half of participants going longer between treatments

Roche today announced one-year results from the Phase IIIb/IV SALWEEN study of Vabysmo® (faricimab) in polypoidal choroidal vasculopathy (PCV); a subtype and difficult to treat form of neovascular or “wet” age-related macular degeneration.

New Survey Highlights Need for Greater Preventive Action to Address Vision Impairment Across Asia Pacific

A new APAC Vision Health Survey, commissioned by Roche, reveals a stark disconnect between vision health concerns and preventive action across Asia Pacific.

Media Enquiries

For Pharma enquiries, please contact:
Tel: +65 6830 9389
Email: [email protected]

For Diagnostics enquiries, please contact:
Tel: +65 9776 7523
Email: [email protected]

For Technical Operations enquiries, please contact:
Tel: +65 64914000

Media releases

One-year Vabysmo data show improved vision, with more than half of participants going longer between treatments

New Survey Highlights Need for Greater Preventive Action to Address Vision Impairment Across Asia Pacific

New study shows Roche’s Vabysmo improves vision in Asian patients with

EVRYSDI® (risdiplam) becomes the first SMA treatment on MAF

STCC joins the Roche imCORE Network as first Southeast Asian member

Tecentriq® SC the first injectable anti-PD-(L)1 cancer immunotherapy

POLIVY® (polatuzumab vedotin) added to the Singapore Cancer Drug List

Rare & Share dining experience to raise awareness and funds for SMA

Roche’s Alecensa reduces the risk of disease recurrence or de

Roche Singapore celebrates 50 years - a joint journey in evolving Sing

Tecentriq plus chemotherapy in extensive-stage small cell lung cancer

Media Enquiries